본문 바로가기
KERD
논문KCI 등재

Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy

Seok Lee|Jae-Ho Yoon
대한내과학회 (The Korean Association Of Internal Medicine)|2024.01|The Korean Journal of Internal Medicine|제39권 제1호|pp. 34-56|DOI 10.3904/kjim.2023.407

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

adultHematopoietic stem cell transplantationLymphoblastic leukemiaacuteImmunotherapyMinimal residual diseaseCytogenetics
주제분류내과학

초록

Acute lymphoblastic leukemia (ALL) is one of the most rapidly changing hematological malignancies with advanced understanding of the genetic landscape, detection methods of minimal residual disease (MRD), and the development of immunotherapeutic agents with good clinical outcomes. The annual incidence of adult ALL in Korea is 300–350 patients per year. The WHO classification of ALL was revised in 2022 to reflect the molecular cytogenetic features and suggest new adverse- risk subgroups, such as Ph-like ALL and ETP-ALL. We continue to use traditional adverse-risk features and cytogenetics, with MRD-directed post-remission therapy including allogeneic hematopoietic cell transplantation. However, with the introduction of novel agents, such as ponatinib, blinatumomab, and inotuzumab ozogamicin incorporated into frontline therapy, good MRD responses have been achieved, and overall survival outcomes are improving. Accordingly, some clinical trials have suggested a possible era of chemotherapy-free or transplantation-free approaches in the near future. Nevertheless, relapse of refractory ALL still occurs, and some poor ALL subtypes, such as Ph-like ALL and ETP-ALL, are unsolved problems for which novel agents and treatment strategies are needed. In this review, we summarize the currently applied diagnostic and therapeutic practices in the era of advanced genetic analysis and targeted immunotherapies in United States and Europe and introduce real-world Korean data.

Abstract

Acute lymphoblastic leukemia (ALL) is one of the most rapidly changing hematological malignancies with advanced understanding of the genetic landscape, detection methods of minimal residual disease (MRD), and the development of immunotherapeutic agents with good clinical outcomes. The annual incidence of adult ALL in Korea is 300–350 patients per year. The WHO classification of ALL was revised in 2022 to reflect the molecular cytogenetic features and suggest new adverse- risk subgroups, such as Ph-like ALL and ETP-ALL. We continue to use traditional adverse-risk features and cytogenetics, with MRD-directed post-remission therapy including allogeneic hematopoietic cell transplantation. However, with the introduction of novel agents, such as ponatinib, blinatumomab, and inotuzumab ozogamicin incorporated into frontline therapy, good MRD responses have been achieved, and overall survival outcomes are improving. Accordingly, some clinical trials have suggested a possible era of chemotherapy-free or transplantation-free approaches in the near future. Nevertheless, relapse of refractory ALL still occurs, and some poor ALL subtypes, such as Ph-like ALL and ETP-ALL, are unsolved problems for which novel agents and treatment strategies are needed. In this review, we summarize the currently applied diagnostic and therapeutic practices in the era of advanced genetic analysis and targeted immunotherapies in United States and Europe and introduce real-world Korean data.

참고문헌 (191)

  1. Inaba H, "Acute lymphoblastic leukaemia", Lancet, 381, pp.1943~1955 (2013)
  2. Moorman AV, "The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia", Blood Rev, 26, pp.123~135 (2012)
  3. Moorman AV, "New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia", Haematologica, 101, pp.407~416 (2016)
  4. Schwab CJ, "Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia : association with cytogenetics and clinical features", Haematologica, 98, pp.1081~1088 (2013)
  5. Liu Y, "The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia", Nat Genet, 49, pp.1211~1218 (2017)
  6. Ladetto M, "Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders", Leukemia, 28, pp.1299~1307 (2014)
  7. Logan AC, "Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival", Biol Blood Marrow Transplant, 20, pp.1307~1313 (2014)
  8. van Dongen JJ, "Minimal residual disease diagnostics in acute lymphoblastic leukemia : need for sensitive, fast, and standardized technologies", Blood, 125, pp.3996~4009 (2015)
  9. Jain N, "Early T-cell precursor acute lymphoblastic leukemia", lymphoma(ETP-ALL, Blood, pp.2016, 127[DOI]
  10. Mullighan CG, "BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros", Nature, 453, pp.110~114 (2008)
  11. Den Boer ML, "A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome : a genome-wide classification study", Lancet Oncol, 10, pp.125~134 (2009)
  12. Lee JW, "Differing outcomes of patients with high hyperdiploidy and ETV6-RUNX1rearrangement in Korean pediatric precursor B cell acute lymphoblastic leukemia", Cancer Res Treat, 53, pp.567~575 (2021)
  13. Jabbour E, "The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades", J Hematol Oncol, 16, pp.22~ (2023)
  14. Baek DW, "Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed", refractory adult T-cell acute lymphoblastic leukemia, 2021, pp.14, 765~775
  15. Cordo’ V, "T-cell acute lymphoblastic leukemia : a roadmap to targeted therapies", Blood Cancer Discov, 2, pp.19~31 (2020)
  16. Alaggio R, "The 5th edition of the World Health Organization classification of haematolymphoid tumours : lymphoid neoplasms", Leukemia, 36, pp.1720~1748 (2022)
  17. Thomas X, "Philadelphia chromosome positive adult acute lymphoblastic leukemia : characteristics, prognostic factors and treatment outcome", Hematol Cell Ther, 40, pp.119~128 (1998)
  18. Dombret H, "Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial", Blood, 100, pp.2357~2366 (2002)
  19. Daver N, "Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia", Haematologica, 100, pp.653~661 (2015)
  20. Lee KH, "Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia", Leukemia, 19, pp.1509~1516 (2005)
  21. Lee S, "The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia", Blood, 105, pp.3449~3457 (2005)
  22. Lee S, "The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia", Cancer, 115, pp.561~570 (2009)
  23. Lee S, "Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia", Leukemia, 26, pp.2367~2374 (2012)
  24. Yanada M, "High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia:a phase II study by the Japan Adult Leukemia Study Group", J Clin Oncol, 24, pp.460~466 (2006)
  25. Bassan R, "Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia : Northern Italy Leukemia Group protocol 09", 00, 2010, pp.28, 3644~3652
  26. Ravandi F, "Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia", Cancer, 121, pp.4158~4164 (2015)
  27. Ravandi F, "US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in philadelphia chromosome positive ALL", Blood Adv, 1, pp.250~259 (2016)
  28. Yoon JH, "Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia", Ann Oncol, 27, pp.1081~1088 (2016)
  29. Martinelli G, "INCB84344-201 : Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia", Blood Adv, 6, pp.1742~1753 (2022)
  30. Kantarjian H, "Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia : 80-months follow-up results", Am J Hematol, 98, pp.493~501 (2023)
  31. Sasaki K, "Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia : a propensity score analysis", Cancer, 122, pp.3650~3656 (2016)
  32. Jabbour E, "Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia : long-term follow-up of a single-centre, phase 2study", Lancet Haematol, 5, pp.e618~e627 (2018)
  33. Roberts KG, "Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia", Cancer Cell, 22, pp.153~166 (2012)
  34. Russell LJ, "Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia", Blood, 114, pp.2688~2698 (2009)
  35. Palmi C, "Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia", Leukemia, 26, pp.2245~2253 (2012)
  36. Roberts KG, "Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia", N Engl J Med, 371, pp.1005~1015 (2014)
  37. Lengline E, "Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion", Haematologica, 98, pp.e146~e148 (2013)
  38. Weston BW, "Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia", J Clin Oncol, 31, pp.e413~e416 (2013)
  39. Cho H, "Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia", Bone Marrow Transplant, 56, pp.1953~1963 (2021)
  40. Guru Murthy GS, "Incidence and survival of T-cell acute lymphoblastic leukemia in the United States", Leuk Lymphoma, 60, pp.1171~1178 (2019)
  41. Litzow MR, "How I treat T-cell acute lymphoblastic leukemia in adults", Blood, 126, pp.833~841 (2015)
  42. Dores GM, "Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007", Blood, 119, pp.34~43 (2012)
  43. Rowe JM, "Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII", ECOG E2993, 2005, pp.106, 3760~3767
  44. Marks DI, "T-cell acute lymphoblastic leukemia in adults : clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial(UKALL XII", ECOG 2993), 2009, pp.114, 5136~5145
  45. Lazarus HM, "Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII", ECOG E2993, 2006, pp.108, 465~472
  46. Coustan-Smith E, "Early T-cell precursor leukaemia : a subtype of very high-risk acute lymphoblastic leukaemia", Lancet Oncol, 10, pp.147~156 (2009)
  47. Inukai T, "Clinical significance of early T-cell precursor acute lymphoblastic leukaemia : results of the Tokyo Children’s Cancer Study Group Study L99-15", Br J Haematol, 156, pp.358~365 (2012)
  48. Ma M, "Early T-cell precursor leukemia : a subtype of high risk childhood acute lymphoblastic leukemia", Front Med, 6, pp.416~420 (2012)
  49. Patrick K, "Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003", Br J Haematol, 166, pp.421~424 (2014)
  50. Genescà E, "Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia", Haematologica, 105, pp.e294~e297 (2020)
  51. Bond J, "Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia : a group for research on adult acute lymphoblastic leukemia study", J Clin Oncol, 35, pp.2683~2691 (2017)
  52. Yoon JH, "Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia", Cancer, 125, pp.873~883 (2019)
  53. Yoon JH, "Cytogenetic and molecular characteristics and outcomes of adult patients with early T-cell precursor acute lymphoblastic leukemia", Eur J Haematol, 110, pp.137~148 (2023)
  54. Lazaryan A, "Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research", Haematologica, 105, pp.1329~1338 (2020)
  55. Mullighan CG, "Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia", N Engl J Med, 360, pp.470~480 (2009)
  56. Kim M, "Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL", Bone Marrow Transplant, 50, pp.354~362 (2015)
  57. Stanulla M, "IKZF1plus Defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia", J Clin Oncol, 36, pp.1240~1249 (2018)
  58. Zhang W, "Prognostic significance of CDKN2A", B deletions in acute lymphoblastic leukaemia : a meta-analysis, 2019, pp.51, 28~40
  59. Yoon JH, "Adverse prognostic role of copy number alterations and mutations in adults with philadelphia chromosome-negative acute lymphoblastic leukemia", Blood, 142(Suppl 1), pp.4342~ (2023)
  60. Berry DA, "Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia : a meta-analysis", JAMA Oncol, 3, pp.e170580~ (2017)
  61. Ribera JM, "Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia", Blood, 137, pp.1879~1894 (2021)
  62. Yilmaz M, "The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival", Am J Hematol, 95, pp.144~150 (2020)
  63. Short NJ, "Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia : a consensus of North American experts", Am J Hematol, 94, pp.257~265 (2019)
  64. Chong SL, "Impact of timely BCR-ABL1 monitoring before allogeneic stem cell transplantation among patients with BCR-ABL1-positive B-acute lymphoblastic leukemia", Blood Res, 56, pp.175~183 (2021)
  65. Bassan R, "Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease(MRD)in adult acute lymphoblastic leukemia(ALL)", Blood, 113, pp.4153~4162 (2009)
  66. Bassan R, "Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years : NILG ALL 10", 07, 2020, pp.10, 119~
  67. Chiaretti S, "A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients : final results of the GIMEMA LAL1509 protocol", Haematologica, 106, pp.1828~1838 (2021)
  68. Foà R, "Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults", N Engl J Med, 383, pp.1613~1623 (2020)
  69. Chiaretti S, "P353 : forty months update of the GIMEMA LAL2116(D-ALBA)protocol and ancillary LAL2217 study for newly diagnosed adult PH+ ALL", HemaSphere, 6, pp.253~254 (2022)
  70. Jabbour E, "Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia : a US, single-centre, single-arm, phase 2 trial", Lancet Haematol, 10, pp.e24~e34 (2023)
  71. Breit TM, "Extensive junctional diversity of gamma delta T-cell receptors expressed by T-cell acute lymphoblastic leukemias : implications for the detection of minimal residual disease", Leukemia, 5, pp.1076~1086 (1991)
  72. d’Auriol L, "In vitro amplification of T cell gamma gene rearrangements : a new tool for the assessment of minimal residual disease in acute lymphoblastic leukemias", Leukemia, 3, pp.155~158 (1989)
  73. Yamada M, "Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region(CDR-III)-specific probes", Proc Natl Acad Sci U S A, 86, pp.5123~5127 (1989)
  74. Beishuizen A, "Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias : a new molecular target for detection of minimal residual disease", Leukemia, 11, pp.2200~2207 (1997)
  75. Szczepański T, "Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease", Blood, 99, pp.2315~2323 (2002)
  76. van der Velden VH, "Age-related patterns of immunoglobulin and T-cell receptor gene rearrangements in precursor-B-ALL : implications for detection of minimal residual disease", Leukemia, 17, pp.1834~1844 (2003)
  77. van Dongen JJ, "Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations : report of the BIOMED-2 Concerted Action BMH4-CT98-3936", Leukemia, 17, pp.2257~2317 (2003)
  78. Hein K, "Clinical value of measurable residual disease in acute lymphoblastic leukemia", Blood Lymphat Cancer, 12, pp.7~16 (2022)
  79. Porwit-MacDonald A, "BIOMED-1concerted action report : flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia(T-ALL)", Leukemia, 14, pp.816~825 (2000)
  80. Coustan-Smith E, "Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia", Blood, 96, pp.2691~2696 (2000)
  81. Lúcio P, "Flow cytometric analysis of normal B cell differentiation : a frame of reference for the detection of minimal residual disease in precursor-B-ALL", Leukemia, 13, pp.419~427 (1999)
  82. Dworzak MN, "Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia", Blood, 99, pp.1952~1958 (2002)
  83. Theunissen P, "Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia", Blood, 129, pp.347~357 (2017)
  84. Wu D, "Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH", Clin Cancer Res, 20, pp.4540~4548 (2014)
  85. Brown PA, "Acute Lymphoblastic Leukemia, Version 2. 2021, NCCN Clinical Practice Guidelines in Oncology", J Natl Compr Canc Netw, 19, pp.1079~1109 (2021)
  86. Ravandi F, "Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy", Blood, 122, pp.1214~1221 (2013)
  87. Gökbuget N, "Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies", Blood, 120, pp.1868~1876 (2012)
  88. Ribera JM, "Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry : final results of the PETHEMA ALLAR-03 trial", J Clin Oncol, 32, pp.1595~1604 (2014)
  89. Kantarjian HM, "Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard-and high-risk acute lymphocytic leukemia", J Clin Oncol, 8, pp.994~1004 (1990)
  90. Kantarjian HM, "Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia", J Clin Oncol, 18, pp.547~561 (2000)
  91. Kantarjian H, "Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone(Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia", Cancer, 101, pp.2788~2801 (2004)
  92. Abaza Y, "Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma", Am J Hematol, 93, pp.91~99 (2018)
  93. Dunsmore KP, "Children’s Oncology Group AALL0434 : A phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia", J Clin Oncol, 38, pp.3282~3293 (2020)
  94. Thomas DA, "Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia", J Clin Oncol, 28, pp.3880~3889 (2010)
  95. Jabbour E, "Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia : a single-arm, phase 2 trial", Lancet Haematol, 7, pp.e523~e533 (2020)
  96. Sasaki K, "Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia : a propensity score analysis", Cancer, 127, pp.3381~3389 (2021)
  97. Stock W, "What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies", Blood, 112, pp.1646~1654 (2008)
  98. Siegel SE, "Pediatric-inspired treatment regimens for adolescents and young adults with philadelphia chromosome-negative acute lymphoblastic leukemia : a review", JAMA Oncol, 4, pp.725~734 (2018)
  99. Boissel N, "Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials", J Clin Oncol, 21, pp.774~780 (2003)
  100. de Bont JM, "Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands", Leukemia, 18, pp.2032~2035 (2004)
  101. Hallböök H, "Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden : a comparison between a pediatric protocol and an adult protocol", Cancer, 107, pp.1551~1561 (2006)
  102. Rytting ME, "Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults(AYAs)with acute lymphoblastic leukemia(ALL)", Cancer, 120, pp.3660~3668 (2014)
  103. Baek DW, "Pediatric-inspired regimen with late intensification and increased dose of L-asparaginase for adult acute lymphoblastic leukemia : the KALLA 1406", 1407 study, 2021, pp.36, 1471~1485
  104. Baek DW, "Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study", Korean J Intern Med, 38, pp.734~746 (2023)
  105. Kim DY, "Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia", Blood, 126, pp.746~756 (2015)
  106. Kantarjian H, "Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia : a single-arm, phase 2 study", Lancet Oncol, 19, pp.240~248 (2018)
  107. Haddad F, "P373 : updates from a phase ii trial of mini-hyper-cvd-inotuzumab with or without blinatumomab in older patients with newly diagnosed Philadelphia chromosome(PH)-negative acute lymphoblastic leukemia", Hemasphere, 7(Suppl), pp.e3563066~ (2023)
  108. Short N, "P358 : hyper-CVAD with blinatumomab and inotuzumab ozogamicin for patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia : a phase II study", Hemasphere, 7(Suppl), pp.e67564ca~ (2023)
  109. Jabbour E, "Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia : long-term results of an open-label phase 2 trial", Lancet Haematol, 10, pp.e433~e444 (2023)
  110. Cortes JE, "Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia : final 5-year results of the phase 2 PACE trial", Blood, 132, pp.393~404 (2018)
  111. Liam CCK, "Philadelphia-positive(PH+)acute lymphoblastic leukemia(ALL) : developing strategies for curing this stubborn disease", Blood Res, 57, pp.158~161 (2022)
  112. Jabbour E, "First report of PhALLCON : A phase 3 study comparing ponatinib(pon)vs imatinib(im)in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia(Ph+ALL)", J Clin Oncol, 41(36 Suppl), pp.398868~398868 (2023)
  113. Ribera JM, "Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia", Blood Adv, 6, pp.5395~5402 (2022)
  114. Nguyen D, "A phase II study of the sequential combination of low-intensity chemotherapy(minihyper-CVD)and ponatinib followed by blinatumomab and ponatinib in patients with Philadelphia chromosome-positive(Ph+)acute lymphoblastic leukemia(ALL)", Blood, 140(Supplement 1), pp.6127~6129 (2022)
  115. Litzow MR, "Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission : results from the ECOG-ACRIN E1910 randomized phase III National Cooperative Clinical Trials Network Trial", Blood, 140(Supplement 2), pp.LBA–1~ (2022)
  116. Eom KS, "Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission", Am J Hematol, 88, pp.634~641 (2013)
  117. Cho BS, "Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission : results of a prospective phase 2 study", Leukemia, 23, pp.1763~1770 (2009)
  118. Jang W, "Prognostic impact of total body irradiation dose in pediatric acute lymphoblastic leukemia patients treated with allogeneic hematopoietic stem cell transplantation in second complete remission", Blood Res, 57, pp.256~263 (2022)
  119. Cahu X, "Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT", Bone Marrow Transplant, 51, pp.351~357 (2016)
  120. Yoon JH, "Impact of donor type on long-term graft-versus-host disease-free", relapse-free survival for adult acute lymphoblastic leukemia in first remission, 2021, pp.56, 828~840
  121. Yoon JH, "Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia : high-risk features for early and long-term mortality", Ther Adv Hematol, 13, pp.20406207221076762~ (2022)
  122. Lee S, "Selecting the right alternative donor : comparison of outcomes of HLA-mismatched alternative donor hematopoietic cell transplantations in adult patients with acute lymphoblastic leukemia regarding KIR-ligand mismatch", Blood, 142(Supplement 1), pp.2247~ (2023)
  123. Gökbuget N, "Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia", Blood, 131, pp.1522~1531 (2018)
  124. Goekbuget N, "Blinatumomab for minimal residual disease(MRD)in adults with B-cell precursor acute lymphoblastic leukemia(BCP-ALL) : median overall survival(OS)is not reached in complete MRD responders at a median follow-up of 53. 1 months", Blood, 132(Supplement 1), pp.554~ (2018)
  125. Gökbuget N, "Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia", Leuk Lymphoma, 61, pp.2665~2673 (2020)
  126. Jabbour EJ, "Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher", Am J Hematol, 97, pp.1135~1141 (2022)
  127. Nasr LF, "Inotuzumab ozogamicin(INO)for the treatment of measurable residual disease(MRD)in patients with B-cell acute lymphoblastic leukemia(B-ALL) : results from a phase II study", J Clin Oncol, 41(16 Suppl), pp.e19008~e19008 (2023)
  128. Metheny L, "Multicenter phase I study of post-transplant low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia", Blood, 140(Supplement 1), pp.1887~1889 (2022)
  129. Gökbuget N, "Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation", Blood, 120, pp.2032~2041 (2012)
  130. Fielding AK, "Outcome of 609adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12", ECOG 2993 study, 2007, pp.109, 944~950
  131. Tavernier E, "Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial", Leukemia, 21, pp.1907~1914 (2007)
  132. Gökbuget N, "International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed", refractory acute lymphoblastic leukemia, 2016, pp.101, 1524~1533
  133. Klinger M, "Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19", CD3-bispecific BiTE antibody blinatumomab, 2012, pp.119, 6226~6233
  134. Hoffmann P, "Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-", CD3-bispecific single-chain antibody construct, 2005, pp.115, 98~104
  135. Maude SL, "Chimeric antigen receptor T cells for sustained remissions in leukemia", N Engl J Med, 371, pp.1507~1517 (2014)
  136. Advani A, "Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma : results of a phase I study", J Clin Oncol, 28, pp.2085~2093 (2010)
  137. Kantarjian H, "Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia", N Engl J Med, 376, pp.836~847 (2017)
  138. Gökbuget N, "Blinatumomab vs historical standard therapy of adult relapsed", refractory acute lymphoblastic leukemia, 2016, pp.6, e473~
  139. Topp MS, "Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia : a multicentre, single-arm, phase 2 study", Lancet Oncol, 16, pp.57~66 (2015)
  140. Martinelli G, "Complete hematologic and molecular response in adult patients with relapsed", refractory Philadelphia chromosome–positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab : results from a phase II, single-arm, multicenter study, 2017, pp.35, 1795~1802
  141. Martinelli G, "Long-term follow-up of blinatumomab in patients with relapsed", refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia : final analysis of ALCANTARA study, 2021, pp.146, 107~114
  142. Haddad F, "P379 : ponatinib and blinatumomab in relapsed", refractory Philadelphia-positive acute lymphoblastic leukemia or chronic myeloid leukemia in lymphoid blast phase : subgroup analysis from a phase II trial, 2023, pp.7(Suppl), e6913408~
  143. Kantarjian H, "Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia", Cancer, 119, pp.2728~2736 (2013)
  144. Jabbour E, "Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody", Am J Hematol, 90, pp.193~196 (2015)
  145. Kantarjian HM, "Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia", N Engl J Med, 375, pp.740~753 (2016)
  146. Kantarjian HM, "Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia : Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study", Cancer, 125, pp.2474~2487 (2019)
  147. Kantarjian HM, "Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia : results from the open-label, randomised, phase 3 INOVATE study", Lancet Haematol, 4, pp.e387~e398 (2017)
  148. Marks DI, "Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia", Biol Blood Marrow Transplant, 25, pp.1720~1729 (2019)
  149. Jabbour E, "Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia : a phase 2 clinical trial", JAMA Oncol, 4, pp.230~234 (2018)
  150. Jabbour E, "Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed", refractory Philadelphia chromosome-negative acute lymphoblastic leukemia, 2021, pp.127, 2025~2038
  151. Kantarjian H, "Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia", J Hematol Oncol, 16, pp.44~ (2023)
  152. Jung SH, "Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed", refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party, 2019, pp.98, 151~158
  153. Yoon JH, "Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage", Cancer Med, 8, pp.7650~7659 (2019)
  154. Yoon JH, "Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia : a propensity scorematched cohort analysis", Ther Adv Hematol, 14, pp.20406207231154713~ (2023)
  155. Lee SH, "Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation : a case study", Int J Hematol, 115, pp.135~139 (2022)
  156. Yoon SY, "Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation", Bone Marrow Transplant, 55, pp.1469~1472 (2020)
  157. Maude SL, "Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia", N Engl J Med, 378, pp.439~448 (2018)
  158. Rives S, "S112 : tisagenlecleucel in pediatric and young adult patients(PTS)WITH relapsed", refractory(R, HemaSphere, pp.2022, 6[DOI]
  159. Pasquini MC, "Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma", Blood Adv, 4, pp.5414~5424 (2020)
  160. Shah BD, "Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia(R", R B-ALL)treated with brexucabtagene autoleucel(brexu-cel)in ZUMA-3, 2023, pp.41(16Suppl), 7023~7023
  161. Shah BD, "KTE-X19 anti-CD19CAR T-cell therapy in adult relapsed", refractory acute lymphoblastic leukemia : ZUMA-3 phase 1 results, 2021, pp.138, 11~22
  162. Shah BD, "KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia : phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study", Lancet, 398, pp.491~502 (2021)
  163. Roddie C, "Safety and efficacy of obecabtagene autoleucel(obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed", refractory adult B-cell acute lymphoblastic leukemia(r, J Clin Oncol, pp.2023, 41(16 Suppl)[DOI]
  164. Yoo JW, "Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor(CAR)T-cell therapy", Blood Res, 58(S1), pp.S20~S28 (2023)
  165. Kim WS, "Phase 1", 2 study of anbalcabtagene autoleucel, novel anti-CD19 CAR-T cell therapy with dual silencing of PD-1 and TIGIT in relapsed or refractory large B-cell lymphoma, 2022, pp.40(16 Suppl), 7522~7522
  166. Berg SL, "Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies:a report from the Children’s Oncology Group", J Clin Oncol, 23, pp.3376~3382 (2005)
  167. Cohen MH, "Approval summary : nelarabine for the treatment of T-cell lymphoblastic leukemia", lymphoma, 2006, pp.12, 5329~5335
  168. Commander LA, "Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed", refractory paediatric T-cell lymphoblastic leukaemia and lymphoma, 2010, pp.150, 345~351
  169. Shimony S, "Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma", leukemia, 2023, pp.7, 1092~1102
  170. Gökbuget N, "High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia", lymphoma offers curative option with subsequent stem cell transplantation, 2011, pp.118, 3504~3511
  171. Candoni A, "Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed", refractory T-cell acute lymphoblastic leukemia, Am J Hematol, pp.2020, 95[DOI]
  172. Chonghaile TN, "Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199", Cancer Discov, 4, pp.1074~1087 (2014)
  173. Shah K, "Venetoclax-resistant T-ALL cells display distinct cancer stem cell signatures and enrichment of cytokine signaling", Int J Mol Sci, 24, pp.5004~ (2023)
  174. Aumann S, "The emerging role of venetoclax-based treatments in acute lymphoblastic leukemia", Int J Mol Sci, 23, pp.10957~ (2022)
  175. Pullarkat VA, "Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma", Cancer Discov, 11, pp.1440~1453 (2021)
  176. Richard-Carpentier G, "Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia", Clin Lymphoma Myeloma Leuk, 20, pp.212~218 (2020)
  177. Samra B, "Outcome of adults with relapsed", refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma, 2020, pp.95, E245~E247
  178. Zappone E, "Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia", Clin Case Rep, 8, pp.2000~2002 (2020)
  179. Yue X, "Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies", Cancer Cell Int, 20, pp.524~ (2020)
  180. Jain N, "A multicenter phase I study combining venetoclax with mini-hyper-CVD in older adults with untreated and relapsed", refractory acute lymphoblastic leukemia, 2019, pp.134(Supplement 1), 3867~
  181. Venugopal S, "A phase II study of mini-hyper-CVD plus venetoclax in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia", Blood, 138(Supplement 1), pp.1239~ (2021)
  182. Gocho Y, "Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia", Nat Cancer, 2, pp.284~299 (2021)
  183. Larson RA, "Managing CNS disease in adults with acute lymphoblastic leukemia", Leuk Lymphoma, 59, pp.3~13 (2018)
  184. Kopmar NE, "How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia", Blood, 141, pp.1379~1388 (2023)
  185. Reman O, "Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and", or at first relapse: results from the GET-LALA group, 2008, pp.32, 1741~1750
  186. Sancho JM, "Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis", Cancer, 106, pp.2540~2546 (2006)
  187. Alfayez M, "Safety and efficacy of blinatumomab in patients with Central Nervous System(CNS)disease : a single institution experience", Blood, 132(Supplement 1), pp.2702~ (2018)
  188. Leahy AB, "CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia : a post-hoc analysis of pooled data from five clinical trials", Lancet Haematol, 8, pp.e711~e722 (2021)
  189. Jacoby E, "CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement : a retrospective international study", Leukemia, 36, pp.1525~1532 (2022)
  190. Lenk L, "Involvement of the central nervous system in acute lymphoblastic leukemia : opinions on molecular mechanisms and clinical implications based on recent data", Cancer Metastasis Rev, 39, pp.173~187 (2020)
  191. Lee JH, "Incidence and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia", Blood, 142(Suppl 1), pp.2210~ (2023)

관련 논문AI추천

재발 및 불응성 급성림프모구백혈병에서의 표적치료제윤재호대한내과학회 · 대한내과학회지2020 · 제95권 제5호Pediatric-inspired regimen with late intensification and increased dose of L-asparaginase for adult acute lymphoblastic leukemia: the KALLA 1406/1407 studyDae Young Kim, Dong Won Baek, Ho-Young Yhim, Joon Ho Moon, Sang Kyun Sohn, Sung-Hoon Jung, Youngil Koh, Yunsuk Choi대한내과학회 · The Korean Journal of Internal Medicine2021 · 제36권 제6호Reduced-intensity chemotherapy with tyrosine kinase inhibitor followed by allogeneic transplantation is effective in patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaDong Won Baek, Do Young Kim, Hee Jeong Cho, Ho Jin Shin, Joon Ho Moon, Jung Min Lee, Mi Hwa Heo, Min Kyoung Kim, Sang Kyun Sohn, Young Rok Do, Young Seob Park대한내과학회 · The Korean Journal of Internal Medicine2025 · 제40권 제1호Acute Lymphoblastic Leukemia in Elderly Patients: A Single Institution’s Experience김기환, 김병국, 김지연, 김현경, 박선양, 범승훈, 신동엽, 양예원, 윤성수, 이동순, 이은영, 이준구, 임유주, 최연악대한내과학회 · The Korean Journal of Internal Medicine2011 · 제26권 제3호필라델피아 염색체-유사 급성 림프모구백혈병의 치료 전략고정숙, 송익찬대한내과학회 · 대한내과학회지2025 · 제100권 제2호Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study이원식, Dae Young Kim, Dong Won Baek, Han-Seung Park, Ho Sup Lee, Hyeon Seok Eom, Inho Kim, Jae-Sook Ahn, Je-Hwan Lee, Joon Ho Moon, Sang Kyun Sohn, Se Ryeon Lee, Sung-Hyun Kim, Yoo Jin Lee, Young Rok Do대한내과학회 · The Korean Journal of Internal Medicine2023 · 제38권 제5호

이 간행물의 다른 논문 (20건)

Could histologic healing be a new treatment target in patients with ulcerative colitis?Soyoung Kim, Sang Hyoung Parkpp. 2-3Now is the time to consider reducing the total ischemic time김동기pp. 4-6Long term management of people with posttuberculosis lung diseaseJu Sang Kim, 김형우, 민진수, Wan Seopp. 7-24Biomarkers of the relationship of particulate matter exposure with the progression of chronic respiratory diseasesWoo Jin Kim, Junghyun Kim, Soo Jie Chungpp. 25-33Comparative study of the efficacy and safety of Abexol (suspension versus tablets) in patients with gastrointestinal symptomsDiana Margarita Rey Kaba, Sarahi Mendoza Castaño, Julio César Fernández Travieso, Yenney Reyes Nuñez, Alfredo Hierro González, Yoandy Hernández Casas, Susana Borges González, María de los Angeles Camacho Morales, Elena Ferrer Batallie, Anaisa Roja Carralera, Maytee Robaina Garcíapp. 57-67
원문 보기